Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) surged 15% after receiving a key regulatory boost from the U.S. Food and Drug ...

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best low priced pharma stocks to buy now. On June 30, Rocket ...

Rocket Pharma receives US FDA regenerative medicine advanced therapy designation for RP-A601 gene therapy: Cranbury, New Jersey Saturday, July 19, 2025, 15:00 Hrs [IST] Rocket Pha ...

Rocket Pharmaceuticals received a regenerative medicine advanced therapy designation from the Food and Drug Administration for its heart disease treatment.

Rocket Pharmaceuticals is acquiring Renovacor, a gene therapies developer whose lead program addresses a particular genetic mutation that leads to a type of heart failure. The all-stock deal gives ...

COO and President of Rocket Pharmaceuticals, Kinnari Patel’s, shares how the company is using gene therapy to eradicate diseases in children.

Image: Courtesy of Rocket Pharma. RCKT Rocket Pharmaceuticals Inc. $2.80-0.36 % Stock Score Locked: Edge Members Only. Benzinga Rankings give you vital metrics on any stock – anytime.

Rocket Pharmaceuticals is reviving the gene therapy market with promising early efficacy results. Find out if RCKT stock can rebound to $50 levels.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.

Rocket Pharmaceuticals RP-A501 Phase II Trial Design (Rocket Pharmaceuticals) While three ex-vivo therapies in Rocket's pipeline show promise, RP-A501 appears to be the leading asset.

(RTTNews) - Rocket Pharmaceuticals, Inc. (RCKT), a late-stage, clinical biotechnology company with genetic therapies for rare childhood disorders, Tuesday announced its agreement to acquire ...